Cargando…
Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors
BACKGROUND: Monoamine oxidase inhibitors (MAOIs) are being developed for major depressive disorder, Alzheimer’s, and Parkinson’s Disease. Newer MAOIs have minimal sensitivity to tyramine, but a key limitation for optimizing their development is that standards for in vivo monoamine oxidase-A (MAO-A)...
Autores principales: | Chiuccariello, Lina, Cooke, Robert G, Miler, Laura, Levitan, Robert D, Baker, Glen B, Kish, Stephen J, Kolla, Nathan J, Rusjan, Pablo M, Houle, Sylvain, Wilson, Alan A, Meyer, Jeffrey H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772270/ https://www.ncbi.nlm.nih.gov/pubmed/26316187 http://dx.doi.org/10.1093/ijnp/pyv078 |
Ejemplares similares
-
Phase 2 Trial of Monoamine Oxidase Inhibitor Phenelzine in Biochemical Recurrent Prostate Cancer
por: Gross, Mitchell E., et al.
Publicado: (2020) -
Monoamine Oxidase A in Antisocial Personality Disorder and Borderline Personality Disorder
por: Kolla, Nathan J., et al.
Publicado: (2017) -
ABUSE OF MONOAMINE OXIDASE INHIBITORS
por: Ananth, Jambur, et al.
Publicado: (1995) -
Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies
por: Naoi, Makoto, et al.
Publicado: (2022) -
Monoamine Oxidase-A Genetic Variants and Childhood Abuse Predict Impulsiveness in Borderline Personality Disorder
por: Kolla, Nathan J., et al.
Publicado: (2017)